Januario E. Castro

9.4k total citations
124 papers, 2.3k citations indexed

About

Januario E. Castro is a scholar working on Genetics, Oncology and Immunology. According to data from OpenAlex, Januario E. Castro has authored 124 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Genetics, 51 papers in Oncology and 45 papers in Immunology. Recurrent topics in Januario E. Castro's work include Chronic Lymphocytic Leukemia Research (62 papers), CAR-T cell therapy research (37 papers) and Lymphoma Diagnosis and Treatment (31 papers). Januario E. Castro is often cited by papers focused on Chronic Lymphocytic Leukemia Research (62 papers), CAR-T cell therapy research (37 papers) and Lymphoma Diagnosis and Treatment (31 papers). Januario E. Castro collaborates with scholars based in United States, United Kingdom and Spain. Januario E. Castro's co-authors include Thomas J. Kipps, Michael Y. Choi, Laura Z. Rassenti, Dennis A. Carson, Desheng Lu, Jian Yu, Liguang Chen, Charles Prussak, George F. Widhopf and Danelle F. James and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Januario E. Castro

118 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Januario E. Castro United States 25 1.1k 808 733 682 523 124 2.3k
Gaël Roué Spain 33 1.7k 1.6× 864 1.1× 568 0.8× 552 0.8× 699 1.3× 101 3.0k
Ryan M. Young United States 19 976 0.9× 809 1.0× 753 1.0× 741 1.1× 1.2k 2.3× 36 2.6k
Christian P. Pallasch Germany 23 1.3k 1.2× 401 0.5× 407 0.6× 554 0.8× 237 0.5× 53 2.3k
Mitomu Kioi Japan 23 1.5k 1.4× 909 1.1× 258 0.4× 701 1.0× 168 0.3× 63 3.5k
Jian Yu China 20 1.1k 1.1× 584 0.7× 347 0.5× 421 0.6× 214 0.4× 69 1.8k
Jean‐Baptiste Telliez United States 28 1.2k 1.1× 807 1.0× 237 0.3× 763 1.1× 206 0.4× 36 2.9k
Xiuli Wu China 24 1.0k 1.0× 718 0.9× 311 0.4× 816 1.2× 92 0.2× 145 2.4k
Yasuto Akiyama Japan 27 878 0.8× 937 1.2× 200 0.3× 708 1.0× 166 0.3× 128 2.2k
Claudia Kowolik United States 26 1.6k 1.5× 1.3k 1.6× 214 0.3× 739 1.1× 288 0.6× 43 2.9k
Keith Dredge United States 30 2.2k 2.1× 983 1.2× 359 0.5× 613 0.9× 286 0.5× 55 3.7k

Countries citing papers authored by Januario E. Castro

Since Specialization
Citations

This map shows the geographic impact of Januario E. Castro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Januario E. Castro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Januario E. Castro more than expected).

Fields of papers citing papers by Januario E. Castro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Januario E. Castro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Januario E. Castro. The network helps show where Januario E. Castro may publish in the future.

Co-authorship network of co-authors of Januario E. Castro

This figure shows the co-authorship network connecting the top 25 collaborators of Januario E. Castro. A scholar is included among the top collaborators of Januario E. Castro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Januario E. Castro. Januario E. Castro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
García-Robledo, Juan Esteban, et al.. (2025). CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology – A comprehensive analysis of clinical trials. Critical Reviews in Oncology/Hematology. 209. 104648–104648. 7 indexed citations
2.
García-Robledo, Juan Esteban, et al.. (2024). Cellular therapies in rheumatic and musculoskeletal diseases. Journal of Translational Autoimmunity. 10. 100264–100264. 5 indexed citations
3.
García-Robledo, Juan Esteban, et al.. (2023). ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype. Frontiers in Oncology. 13. 1200914–1200914. 22 indexed citations
4.
García-Robledo, Juan Esteban, Cristina Valencia-Sánchez, Brent P. Goodman, et al.. (2022). It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy. SHILAP Revista de lepidopterología. 15(1). 1–8.
5.
Iqbal, Madiha, Radhika Bansal, Allison Rosenthal, et al.. (2022). Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 28(10). 668.e1–668.e6. 5 indexed citations
7.
Ensign, Shannon P. Fortin, Michael W. Ruff, Januario E. Castro, et al.. (2022). Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Current Treatment Options in Oncology. 23(12). 1845–1860. 6 indexed citations
8.
García-Robledo, Juan Esteban, et al.. (2021). Preclinical NK Cell Platform for CAR Directed Therapies: Functional and Phenotypic Comparison Using a Rechallenge Cytotoxicity Assay. Blood. 138(Supplement 1). 4805–4805. 2 indexed citations
9.
Rahman, Zaid Abdel, et al.. (2021). Predictors and Management of Relapse to Axicabtagene Ciloleucel in Patients with Aggressive B-cell Lymphoma ☆. Hematology/Oncology and Stem Cell Therapy. 16(2). 133–143. 7 indexed citations
10.
Rahman, Zaid Abdel, Hollie Saunders, Allison Rosenthal, et al.. (2020). C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel ☆. Hematology/Oncology and Stem Cell Therapy. 14(2). 141–146. 4 indexed citations
14.
Kashyap, Manoj Kumar, Deepak Kumar, Brett H. Simmons, et al.. (2017). Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. Journal of Hematology & Oncology. 10(1). 112–112. 49 indexed citations
15.
Castro, Januario E., et al.. (2012). Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 Molecule. Cancer Research. 72(12). 2937–2948. 34 indexed citations
16.
Lu, Desheng, Michael Y. Choi, Jian Yu, et al.. (2011). Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proceedings of the National Academy of Sciences. 108(32). 13253–13257. 330 indexed citations
18.
Hoff, Daniel D. Von, M. Beeram, Januario E. Castro, et al.. (2007). Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor. Molecular Cancer Therapeutics. 6. 1 indexed citations
19.
Bashey, Asad, Bridget Medina, Jiehua Zhou, et al.. (2005). Phase I study of a neutralizing monoclonal anti-CTLA4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 11(2). 5–5. 2 indexed citations
20.
Castro, Januario E., et al.. (1996). Proteinas de union a dna. 7(3). 163–172. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026